Structure Therapeutics Announces Positive Clinical Trial Results

Structure Therapeutics, Inc. Sponsored ADR ( (GPCR) ) has shared an announcement.

On December 8, 2025, Structure Therapeutics announced positive results from its ACCESS clinical program for aleniglipron, a once-daily oral GLP-1 receptor agonist for obesity treatment. The Phase 2b ACCESS study showed significant weight loss with a 120 mg dose, while the exploratory ACCESS II study demonstrated even greater weight loss with a 240 mg dose. The findings support advancing to Phase 3 trials in mid-2026, potentially offering a scalable and accessible treatment option for obesity.

The most recent analyst rating on (GPCR) stock is a Buy with a $50.00 price target. To see the full list of analyst forecasts on Structure Therapeutics, Inc. Sponsored ADR stock, see the GPCR Stock Forecast page.

Spark’s Take on GPCR Stock

According to Spark, TipRanks’ AI Analyst, GPCR is a Underperform.

Structure Therapeutics, Inc.’s overall score is largely impacted by its financial performance, reflecting significant financial sustainability risks due to zero revenues and increasing losses, despite strong cash positions. The technical analysis provides a mixed view with some short-term momentum but longer-term concerns. The valuation remains challenging with a negative P/E ratio, indicating a speculative investment reliant on future success in R&D and commercialization.

To see Spark’s full report on GPCR stock, click here.

More about Structure Therapeutics, Inc. Sponsored ADR

Structure Therapeutics Inc. is a clinical-stage global biopharmaceutical company focused on developing novel oral small molecule therapeutics for metabolic diseases, particularly obesity.

Average Trading Volume: 1,052,170

Technical Sentiment Signal: Buy

Current Market Cap: $2.1B

For detailed information about GPCR stock, go to TipRanks’ Stock Analysis page.